Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at Zacks Investment Research

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday, Zacks.com reports.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

A number of other research firms have also weighed in on ACRS. StockNews.com assumed coverage on Aclaris Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Aclaris Therapeutics in a research note on Friday, February 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Aclaris Therapeutics currently has a consensus rating of “Buy” and an average price target of $30.50.

Shares of NASDAQ:ACRS traded up $0.62 during trading on Monday, reaching $12.94. The stock had a trading volume of 19,760 shares, compared to its average volume of 505,182. The business has a fifty day moving average price of $15.82 and a 200-day moving average price of $14.34. The stock has a market cap of $792.90 million, a PE ratio of -7.94 and a beta of 0.46. Aclaris Therapeutics has a 1-year low of $9.26 and a 1-year high of $25.65.

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) last released its quarterly earnings data on Thursday, February 24th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01). The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $1.80 million. Aclaris Therapeutics had a negative return on equity of 47.82% and a negative net margin of 1,343.96%. Aclaris Therapeutics’s quarterly revenue was down 5.1% compared to the same quarter last year. Research analysts expect that Aclaris Therapeutics will post -1.84 earnings per share for the current year.

In other Aclaris Therapeutics news, CEO Neal Walker sold 20,000 shares of Aclaris Therapeutics stock in a transaction on Monday, April 25th. The stock was sold at an average price of $15.18, for a total value of $303,600.00. Following the sale, the chief executive officer now owns 1,245,763 shares in the company, valued at $18,910,682.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph Monahan sold 30,000 shares of Aclaris Therapeutics stock in a transaction on Monday, April 18th. The shares were sold at an average price of $16.28, for a total value of $488,400.00. Following the completion of the sale, the insider now owns 106,386 shares in the company, valued at approximately $1,731,964.08. The disclosure for this sale can be found here. Insiders sold 171,674 shares of company stock worth $2,699,797 in the last 90 days. Company insiders own 8.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale raised its holdings in shares of Aclaris Therapeutics by 10.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 22,000 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 2,000 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Aclaris Therapeutics in the 1st quarter valued at $8,748,000. Walleye Capital LLC purchased a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at $150,000. AlphaCentric Advisors LLC purchased a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at $989,000. Finally, Barclays PLC raised its holdings in shares of Aclaris Therapeutics by 100.4% in the 4th quarter. Barclays PLC now owns 100,518 shares of the biotechnology company’s stock valued at $1,461,000 after buying an additional 50,349 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Aclaris Therapeutics (Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Read More

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.